Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation

NCT05321498 is registered in ClinicalTrials.gov with Inmune Bio, Inc. as lead sponsor.

NCT NCT05321498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation
Lead sponsor
Inmune Bio, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2023
Completion date
October 26, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, central nervous system diseases, dementia, mental disorders, mild cognitive impairment (mci), nervous system diseases, neurodegenerative diseases, tauopathies